Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Share-based Compensation (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Share-based Compensation for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 29.99% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.7 million, a 24.1% decrease, with the full-year FY2025 number at $12.7 million, down 24.1% from a year prior.
  • Share-based Compensation was $2.7 million for Q4 2025 at Caribou Biosciences, down from $2.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.7 million in Q2 2024 to a low of $343000.0 in Q1 2021.
  • A 5-year average of $2.9 million and a median of $3.1 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 781.63% in 2022, then crashed 33.96% in 2025.
  • Caribou Biosciences' Share-based Compensation stood at $1.6 million in 2021, then surged by 96.51% to $3.1 million in 2022, then increased by 14.67% to $3.6 million in 2023, then grew by 9.98% to $3.9 million in 2024, then decreased by 29.99% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Share-based Compensation are $2.7 million (Q4 2025), $2.9 million (Q3 2025), and $3.1 million (Q2 2025).